What is the half-life of BPC-157?
The published plasma half-life of BPC-157 in preclinical models is reported in the range of minutes to ~4 hours depending on the route of administration and the species studied. The compound’s structural stability against gastric and serum proteases — the basis for the “stable” in its full name “stable gastric pentadecapeptide BPC 157” — is more relevant to its research framing than the short circulating half-life suggests.
What the research literature says
The Sikiric-Seiwerth research group’s three decades of work on BPC-157 has consistently characterised the compound as exceptionally stable against the proteolytic degradation that limits the in-vivo lifetime of most peptides of comparable size. The compound is stable in human gastric juice — the original isolation source — and resistant to many serum proteases. Despite this structural stability, the plasma half-life remains short by the standards of engineered long-acting peptide therapeutics (which are explicitly modified for multi-day half-lives via fatty-acid sidechains and other modifications).
The cross-laboratory replication framework around BPC-157 spans wound-healing models (PMID 34267654), gastrointestinal-protection literature (PMID 38980576), pleiotropic-activity reviews (PMID 38675421), and musculoskeletal-soft-tissue research (PMID 30915550). Across these models the dosing intervals vary — once-daily through twice-weekly depending on the protocol — and the published effects are typically observed at dosing frequencies that exceed what a simple plasma-half-life calculation would predict.
One explanation for this discrepancy is tissue-binding pharmacology: even short-circulating peptides can produce sustained tissue-level effects when they engage cell-surface receptors that internalise and signal beyond the residence-in-plasma window. The VEGFR2 engagement documented in the Hsieh BPC-157 angiogenesis work (PMID 27847966) is one such mechanism with the receptor-internalisation half-life potentially longer than the plasma half-life of the ligand.
Why this matters in research context
The short plasma half-life shapes experimental design considerations. Researchers running acute single-dose pharmacology designs see rapid plasma clearance; researchers running chronic-dosing protocols see the integrated tissue-level effects accumulating across multiple doses. The interpretation of any individual time-course measurement depends on whether the assay is plasma-based (rapid clearance signal) or tissue-effect-based (longer-duration signal). For BPC-157 specifically, the tissue-effect framing is more relevant to most published research than the plasma-clearance framing.
Related compounds
- BPC-157 10mg — the compound covered by this answer
- BPC-157 (glossary entry) — structure, mechanism, regulatory status
- VEGFR2 (glossary entry) — the receptor target with internalisation-time pharmacology relevant to the half-life discussion
Related research questions
References
- Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl) 2017;95(3):323-333. [PMID 27847966]
- Gwyer D et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol 2021;12:627533. [PMID 34267654]
- Sikiric P et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. Inflammopharmacology 2024;32(5):3119-3161. [PMID 38980576]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. BPC-157 is sold strictly as a research-grade reagent for laboratory and bench research applications.